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Introduction {#sec1}
============

The immune system is characterized by enriched polymorphism in genetic control factors, coupled to a high degree of cellular plasticity and sensitivity to environmental drivers. The resulting functional diversity serves as an important control mechanism for limiting the impact of transmissible pathogens on the population. Conversely, this same diversity contributes to the susceptibility or resistance of individuals to a broad set of sterile diseases, from those with an obvious immunological component, such as autoimmunity, allergy, inflammation, and cancer, to the increasingly recognized immune-influenced diseases, such as cardiovascular, metabolic, and neurological diseases. Despite this, the characterization of the genotype-phenotype relationship of the immune system components has lagged behind the vast progress made by genome-wide association studies (GWASs) of emergent diseases.

The recent advent of in-depth immune phenotyping across large sample sizes has enabled characterization of the extent and identification of the factors shaping variation in the human immune profile ([@bib44]). Longitudinal studies have reported a high level of interindividual variation, with low longitudinal variation and a highly elastic structure, where transient antigen-induced changes are followed by a return to the individual's unique baseline ([@bib8], [@bib55], [@bib73]). Twin and family-based studies provide heritability estimates of 20%--40% on average but cover a wide range across individual cellular or cytokine traits ([@bib6], [@bib8], [@bib49], [@bib55], [@bib63]). Aging contributes up to 5% of total immune variation ([@bib2], [@bib6], [@bib8], [@bib55], [@bib58], [@bib67]), and environmental factors shaping the immune system include obesity, cohabitation, and chronic viral infections ([@bib2], [@bib6], [@bib8], [@bib58]).

Identification of the genetic factors controlling variation in the immune system is still in the initial discovery phase, reminiscent of the early days of disease-susceptibility GWASs, with novel and strong associations emerging from the pioneer studies ([@bib2], [@bib55], [@bib58], [@bib63]), but the overlap of loci reported in more than one study is still limited ([@bib43]). Hence, we undertook a GWAS for 54 immune traits enriched for functionally relevant adaptive immune system phenotypes, including 30 T cell and 8 B cell subsets based on proliferation, differentiation, activation, or cytokine production, as well as baseline *ex vivo* plasma levels of ten pro- or anti-inflammatory cytokines. Our GWAS covers the genetic contributions from both common (\>5%) and less common (1%--5%) variants. Genome-wide significant associations explain a median of 10% of variance in adaptive immune system variation and identify variant genes and pathways as key regulators of the adaptive immune system in humans. Coding and splicing variants in *PTPRC* and *COMMD10* are involved in memory T cell differentiation. Genetic variation controlling T helper cell subsets with crucial roles in protection against infection and susceptibility to autoimmune disease include the second mTOR signaling complex (*RICTOR*) and endocytosis-related stonin 2 (*STON2*) associated with Th2 and Th17, respectively, and the interferon-lambda locus controlling regulatory T (Treg) cell proliferation. Early and memory B cell differentiation stages are associated with variation in the as yet poorly characterized genes *LARP1B* and *SP4.* Finally, our results implicate the latrophilin family member *ADGRL2* as genetic variant for baseline pro-inflammatory cytokine production. Our data furthermore unravel the mechanism of action of established genotype-disease associations, involving key cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-2 (IL-2) in autoimmune diseases and granulocyte-macrophage colony-stimulating factor (GM-CSF) in immune-proliferative diseases. Finally, clinical implications resulting from associations in this study offer attractive therapeutic intervention points.

Results {#sec2}
=======

A Genome-Wide Association Screen for Common and Less Common Variants Controlling the Human Adaptive Immune System {#sec2.1}
-----------------------------------------------------------------------------------------------------------------

We performed a GWAS in a study population of 502 healthy white individuals for 54 immune phenotypes. Immune phenotypes were enriched for functionally relevant adaptive immune system parameters and included 42 cellular phenotypes determined by flow cytometry and ten cytokines measured in plasma as described previously ([@bib8]), as well as two DNA markers reflecting newly formed B and T cells (excision circles sjKREC \[kappa-deleting recombination excision circle\] and sjTREC \[T cell receptor excision circle\]) ([@bib74]) ([Table S1](#mmc2){ref-type="supplementary-material"}). We previously demonstrated stability over time for cellular immune variables in a subset of 177 individuals from this dataset who were sampled at multiple time points with an average of 6 months between samplings ([@bib8]). The latest-generation imputation-based genotyping array allowed investigation of up to 10,246,977 autosomal variants with imputation accuracy (INFO) ≥ 0.4, including 6,994,434 common (minor allele frequency \[MAF\] \>5%) and 3,252,543 less common (1 ≤ MAF ≤ 5%) variants in 489 individuals after quality control (QC) ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}).

We observed nominal significance for five genome-wide significant associations previously reported in the Sardinian population ([@bib55]) ([Table 1](#tbl1){ref-type="table"}). Replication of previously known loci demonstrates the reproducibility of our dataset, despite different ethnic composition, different definitions for immunological variables, and independent generation of immune phenotyping platforms.Table 1Replication of Previously Known Genotype-Immune Phenotype AssociationsChrPosrsIDEANEAEAFBETA (SE)p ValueTraitCandidate GenesTrait ([@bib55])238897074rs13011383GA0.87−0.34 (0.12).0070CD4^+^ EMRA*GALM*, *HNRPLL*TD CD4^+^ %GP238921934rs7583259GC0.49−0.31 (0.09).00051CD8^+^ EM*GALM*, *DHX57*, *HNRPLL*CD45RA^−^ CD28^−^ CD8^br^ %P287014377rs2944254CT0.720.25 (0.09).0073CD4^+^ proliferating*CD8A*, *RMND5A*, *CD8B*, *VPS24*CD4^+^ CD8^dim^ AC126899181rs2855537GT0.760.18 (0.08).023TREC*CD4*naive (CD4^+^ CD8^+^) AC1733797371rs9916257TG0.47−0.23 (0.06).00028NK*SLFN13*, *SLFN12L*, *CCL1*NK %GP[^3]

Subsequently, we identified eight regions reaching genome-wide significance (p \< 5 × 10^−8^) to at least one immunological parameter ([Figure 1](#fig1){ref-type="fig"}); all of them were not previously reported. Lead variants in these regions had MAFs between 2% and 37% and explained 6.22% to 20.08% of the variance in the corresponding trait ([Table 2](#tbl2){ref-type="table"}). For all three regions where both trait and variant have appropriate equivalents in three previous GWASs ([@bib2], [@bib55], [@bib63]), our findings replicated with nominal significance (p \< 0.05) or showed a trend in the same direction in publicly available data ([Table S2](#mmc3){ref-type="supplementary-material"}). Of note, the *PTPRC* variant with an MAF 2% fell beyond the scope of common variants in previous GWASs but is identified in our study covering the entire range of common and less common variants. For the other five genome-wide significant regions, the same trait and immunological definition was not investigated in previous GWASs.Figure 1Genome-wide Significant Genotype-Immune Phenotype Associations(A) Circos plot demonstrating eight regions reaching genome-wide significant association with immune phenotypes. The y axis displays the negative logarithm of the p value. Variants reaching genome-wide significance (p \< 5 × 10^−8^, dotted red line) are depicted in red, and the corresponding trait with which the variant is associated is indicated.(B) Overview of the association of eight independent lead variants reaching genome-wide significance to at least one immune phenotype with all 54 immune phenotypes (see also [Table S1](#mmc2){ref-type="supplementary-material"} for definitions of immune phenotypes). Darkest colors indicate genome-wide significant associations, whereas red and blue colors distinguish a positive or negative direction of effect, respectively. Genome-wide (GW) significant, suggestive, nominal, and trend correspond to p values \< 5 × 10^−8^, \< 1 × 10^−4^, \< 0.05, and \< 0.10, respectively.Table 2Novel Genome-wide Significant Genotype-Immune Phenotype AssociationsChrPosrsIDEANEAEAFBETA (SE)% varINFOnp valueTraitGeneAnnotation182196322rs9324185CT0.370.36 (0.06)6.220.984743.51 × 10^−8^IL-6*ADGRL2*G1198665917rs17612648GC0.02−2.04 (0.26)15.700.8833626.22 × 10^−15^CD4^+^ EM*PTPRC*Co, Q, G, L1198665917rs17612648GC0.02−1.76 (0.27)11.840.8593628.94 × 10^−11^CD4^+^ CM*PTPRC*Co, Q, G, L1198830942rs113116201CT0.021.72 (0.29)12.260.9962557.58 × 10^−9^CD4^+^ EMRA*PTPRC*Co, Q, L1198830942rs113116201CT0.02−2.17 (0.27)20.080.9962487.52 × 10^−14^CD8^+^ EM*PTPRC*Co, Q, L4128924522rs373482106CCA0.230.49 (0.08)8.210.9194494.90 × 10^−10^KREC*LARP1B*Q, L, E538974929rs16867919GA0.210.43 (0.08)6.1314753.56 × 10^−8^Th2*RICTOR*R, G, L5115413042rs6886944TC0.67−0.54 (0.10)11.570.9662484.83 × 10^−8^CD8^+^ CM*COMMD10*Co, Q, Cs, N, L721115110rs917812GC0.22−0.46 (0.08)6.870.9674685.86 × 10^−9^Memory B*SP4*Cs, L, E1482778603rs1457990AG0.51−0.36 (0.06)6.560.9984661.91 × 10^−8^Th17*STON2*Cs, L, E1939745146rs10853728GC0.67−0.48 (0.08)9.9512942.89 × 10^−8^proliferating TregIFNλ clusterN, L[^4]

Through a combination of bioinformatics and experimental functional analyses, the biologically most likely candidate gene stood out for all eight genome-wide significant associations. These associations highlight genes with critical roles in the adaptive immune system that have previously been demonstrated in mice but for which human data were lacking so far. Additionally, they shed light on the role of recently described but still poorly characterized protein families. Finally, they have important clinical implications.

Coding and Splicing Variants Involved in T Cell Memory Differentiation {#sec2.2}
----------------------------------------------------------------------

Two of the genome-wide hits correspond to or are in high linkage disequilibrium (LD) with splicing or coding variants ([Figure 2](#fig2){ref-type="fig"}). The single-nucleotide polymorphisms (SNPs) rs17612648 and rs113116201 are in LD (r^2^ = 0.62 in Europeans \[EURs\], r^2^ = 1 in Utah Residents \[CEPH\] with Northern and Western ancestry \[CEU\]), and conditional analyses were not able to distinguish between them ([Table S3](#mmc4){ref-type="supplementary-material"}). However, rs17612648 is a synonymous variant (P59P) located in exon 4 of *PTPRC*, the gene encoding protein-tyrosine phosphatase receptor-type C or CD45. Its minor allele (frequency = 2%) disrupts an exonic splicing silencer and increases levels of the splice form including exon 4 (CD45RA) in T cell lines ([@bib30], [@bib48], [@bib66], [@bib82]). The negative association of this allele with relative percentages of CD45RA^−^ effector memory (EM) and central memory (CM) T cells, and positive association with CD45RA^+^ terminally differentiated memory (EMRA) T cells, reflects persistent isoform expression on the cell surface as a marker for these cells ([Figures 2](#fig2){ref-type="fig"}A--2H).Figure 2Coding and Splicing Variants Involved in T Cell Memory Differentiation(A--H) Regional association plots (A--D) and boxplots (E--H) for *PTPRC* variants with CD4^+^ effector memory (EM) T cells (A and E), CD4^+^ central memory (CM) T cells (B and F), CD4^+^ terminally differentiated (EMRA) T cells (C and G), and CD8^+^ EM cells (D and H). Variant rs17612648 disrupts an exonic splicing silencer for *PTPRC* exon 4 (CD45RA splice form) and is in LD with rs113116201 (see also [Table S3](#mmc4){ref-type="supplementary-material"}).(I and J) Regional association plot (I) and boxplot (J) for the *COMMD10* region with CD8^+^ CM cells. The lead variant rs6886944 is in high LD with synonymous coding variant rs1129494. In regional association plots, the x axis depicts the position on the chromosome and RefSeq genes, the left y axis indicates the negative logarithm of the p value for each variant (with the horizontal line corresponding to genome-wide significance or p \< 5 × 10^−8^), and the right y axis shows recombination rates. The lead variant is indicated with a purple diamond and text, other variants of interest are indicated in blue text, and LD of other variants with the lead variant is color-coded based on r^2^ in the 1000 Genomes November 2014 European (EUR) database. In boxplots, boxes indicate median and interquartile range, with whiskers extending to 1.5× the interquartile range.

Variant rs6886944, associated with CM CD8^+^ T cells, is in near-perfect LD (r^2^ = 0.96) with synonymous variant rs1129494 (T68T) in the fourth exon of the nearest gene, *COMMD10*, a member of the copper metabolism gene MURR1-domain-containing family ([Figures 2](#fig2){ref-type="fig"}I and 2J). These variants overlap with an expression quantitative trait locus (eQTL) for *COMMD10* in lymphoblastoid cell lines (LCL) and monocytes ([@bib42], [@bib80]) and correspond to the peak of association with exon-level expression of *COMMD10* exon 4 in LCL (r^2^ with top-associated exon-level eQTL = 0.99) ([@bib38]).

*RICTOR*, *STON2*, and Lambda Interferons Drive T Helper Differentiation and Proliferation {#sec2.3}
------------------------------------------------------------------------------------------

Naive CD4^+^ T cells can differentiate into functionally distinct subsets characterized by a unique cytokine expression pattern and a lineage-associated transcription factor network. The crucial role of these T helper subsets in infection, autoimmunity, and cancer has been demonstrated extensively. Our previous work indicates that in healthy individuals, baseline T helper differentiation is variant between individuals but stable over time ([@bib8]). Our current study reports three genetic variants associated with T helper cell differentiation and activation ([Figure 3](#fig3){ref-type="fig"}).Figure 3Genetic Variants Associated with T Helper Subset Differentiation and Proliferation(A--G) Regional association (A--C) and boxplots (D--F) for T helper 2 (Th2) (A and D), T helper 17 (Th17) (B and E), and proliferating regulatory T cells (Tregs) (C and F). Legends as in [Figure 2](#fig2){ref-type="fig"}.(G) Lead associated variant in *RICTOR* is predicted to disrupt the T cell transcription factor MEF2-binding site.(H) Among three candidate genes (*STON2*, *SEL1L*, and *LINC01467*) within a 1-Mb interval in the chromosome 14 region, *STON2* was the only gene differentially expressed in Th17 versus Th1 cells differentiated from naive CD4^+^ T cells. Expression of *LINC01467* was undetectable and not shown. *IL17A* and *IFNG* were included as positive controls for Th17 and Th1 cells, respectively. Mean and SEM for triplicate measurements from three donors are shown; relative quantity (RQ) was normalized using a T cell housekeeping gene (*RPL13A*) and was log-transformed for analysis.

Variant rs16867919 is located in an intron of the gene encoding *RICTOR*, part of the second mTOR signaling complex (mTORC2). This variant is predicted to disrupt the binding site for the T cell transcription factor MEF2 ([@bib4]) and was associated with Th2 frequency in humans ([Figures 3](#fig3){ref-type="fig"}A, 3D, and 3G).

SNP rs1457990, associated with Th17 frequency, is located in an intergenic region on chromosome 14 but is highly conserved as predicted by both genomic evolutionary rate profiling (GERP) and site-specific phylogenetic analysis (SiPhy) bioinformatics tools. We measured expression of candidate genes within a 1-Mb interval of the variant (*STON2*, *SEL1L*, and *LINC01467*) in Th17 and Th1 cells differentiated from naive CD4^+^ T cells. We included *IL17A* and *IFNG* as positive controls for Th17 and Th1 cells, respectively. We subsequently demonstrated that *STON2* was the only chromosome 14 candidate gene differentially expressed in Th17 cells. Indeed, *STON2* was upregulated more than two-fold in Th17 versus Th1 cells (2.23 ± 0.19, p = 0.0035), suggesting a cell-intrinsic basis of variance in Th17 frequency ([Figures 3](#fig3){ref-type="fig"}B, 3E, and 3H).

Association with the frequency of Foxp3^+^ Treg cells undergoing proliferation was seen for variant rs10853728. Of note, the minor allele was associated with an increase in percentage of proliferating Treg cells, but not overall Treg cell frequency ([Figure 1](#fig1){ref-type="fig"}B). This is a singleton variant, in weak LD (r^2^ \< 0.2) with any other SNP in the region, but was directly genotyped with the cluster plot passing visual inspection. This variant maps to the locus of the lambda interferons (IFN-λ), intergenic between interferon-lambda-2 (*IFNL2*) and interferon-lambda-4 (*IFNL4*) ([Figures 3](#fig3){ref-type="fig"}C and 3F).

*LARP1B* and *SP4* Are Involved in B Cell Differentiation {#sec2.4}
---------------------------------------------------------

sjKREC excision circles allow quantification of newly formed B cells at the DNA level. Genome-wide significant association for sjKREC levels was seen for multiple variants throughout the *LARP1B* gene, with strongest association for the insertion or deletion variant rs373482106 ([Figures 4](#fig4){ref-type="fig"}A and 4C). Comparison with flow cytometry measurements showed sjKREC levels were correlated most strongly with B cells (r^2^ = 0.33) and naive B cells (r^2^ = 0.22), and nominal association in the same direction was observed for these cell types ([Figure 1](#fig1){ref-type="fig"}B). The region of association overlaps with an eQTL region for *LARP1B* in LCL ([@bib21]). LARP1B belongs to the La-related protein family (LARP) with roles in transcription and/or translation. We demonstrated that treatments known to induce the formation of early B cells, such as interferon-beta ([@bib11]), increase sjKREC excision circles and decrease *LARP1B* gene expression levels, and we observed an inverse correlation between *LARP1B* gene expression and sjKREC levels ([Figures 4](#fig4){ref-type="fig"}E--4G).Figure 4Genetic Variants Associated with B Cell Differentiation(A--G) Regional association plots (A and B) and boxplots (C and D) for sjKREC levels (A and C) and memory B cells (B and D). Treatments known to increase early B cells such as interferon-beta (IFNB) compared to untreated multiple sclerosis patients (UNT) increased KREC levels (E) and decreased *LARP1B* gene expression (F), with an inverse correlation between *LARP1B* and KREC levels (G) (simplex measurements in PBMCs from 82 individuals).(H) Among genes in the chromosome 7 region (*LINC01162*, *SP4*, and *SP8*), only *SP4* is highly expressed in B cell subsets. Mean and SD of gene expression levels (triplicate measurements from four donors) is depicted. Additional legend as in [Figure 2](#fig2){ref-type="fig"}.

Variant rs917812 associated with memory B cells maps adjacent to several genes, including *SP4*, *SP8*, and long-coding RNA *LINC01162* ([Figures 4](#fig4){ref-type="fig"}B and 4D). We measured gene expression *ex vivo* in four B cell subsets (transitional, naive, memory, and switched memory) isolated from healthy donors and found only *SP4* to be highly expressed in all B cell subsets ([Figure 4](#fig4){ref-type="fig"}H).

Genetic Control of Pro-inflammatory Cytokine Production {#sec2.5}
-------------------------------------------------------

Our study also investigated genetic variants underlying baseline differences in *ex vivo* plasma cytokine levels in healthy individuals. SNP rs9324185 was associated at genome-wide significance with plasma interleukin-6 (IL-6) levels ([Figures 5](#fig5){ref-type="fig"}A and 5B). In line with the previously described phenotypic clustering of pro-inflammatory cytokines ([@bib8]), the same variant was associated at nominal significance with other pro-inflammatory cytokines (TNF-α, IL-8, IL-2, and IFNG) ([Figure 1](#fig1){ref-type="fig"}B). No association (not even a trend) was seen for IL-6 gene expression levels in RNA extracted from peripheral blood mononuclear cells (PBMCs) ([Figure 5](#fig5){ref-type="fig"}C), suggesting a possible post-transcriptional mechanism or a non-hematopoietic source of IL-6 underlying the association with IL-6 protein levels. The variant is located within the promoter region of the most common *ADGRL2* splice form and within an intron of an alternatively transcribed splice form. The same locus has been associated with pediatric autoimmune diseases ([@bib40]), although correlation between the variant increasing IL-6 and the autoimmune disease risk variant is poor (r^2^ = 0.055).Figure 5Genetic Control of Pro-inflammatory Cytokine Production(A) Regional association plot for *ex vivo* plasma interleukin-6 levels additionally depicting known GWAS hits in this region, including a variant associated with pediatric autoimmune diseases but in weak LD (r^2^ = 0.055).(B and C) Boxplot for *ex vivo* plasma interleukin-6 levels (B) and interleukin-6 gene expression (C) in RNA extracted from PBMCs (simplex measurements from 173 individuals) (p = 0.16). Additional legend as in [Figure 2](#fig2){ref-type="fig"}.

Genotype-Immune Phenotype Associations Shed Light on Mechanism of Action of Susceptibility Variants for Immune-Related Disorders {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------------

Beyond the associations reaching most robust genome-wide significance (p \< 5 × 10^−8^), suggestive effects have been shown to explain an important proportion of variance in human traits ([@bib68], [@bib78]) and to be enriched for true effects eventually reaching genome-wide significance with larger sample size or replication ([@bib27], [@bib28]). Among 10,984 independent (r^2^ \< 0.1) autosomal lead signals associated with at least one phenotype, 39% fall within the category of less common variants ([Table S4](#mmc5){ref-type="supplementary-material"}). GWAS have enabled extensive progress in the identification of risk variants for immune-related disorders, yet understanding their mechanism of action is a current key challenge. As known risk variants have a higher prior probability of association, we explored their overlap with suggestive variants. Specific genotype-immune phenotype associations and directions of effect thereby provide potential proximal inflammatory mediators between the *cis*-acting impact of the polymorphism and immune disease susceptibility ([Tables 3](#tbl3){ref-type="table"} and [S5](#mmc6){ref-type="supplementary-material"}).Table 3Genotype-Immune Phenotype Correlations for Known Immune Disease Susceptibility LociChrPosrsIDEANEAEAFBETA (SE)p valueTraitDiseaseVariantsGenes2204690355rs231746CG0.490.29 (0.06)4.68 × 10^−6^CD8^+^ IL2^+^RA (+)rs231735^∗^T*CTLA4*318752031rs55845060CT0.170.35 (0.08)8.02 × 10^−5^TNF-αPs (+)rs68080462^∗^C*SATB1*632590924rs3129763AG0.260.35 (0.08)2.93 × 10^−5^lymphocyteSSc (+)rs3129763HLA class II632680928rs7765379TG0.110.51 (0.10)8.90 × 10^−7^TNF-αRA, CD, EF (+)rs7765379HLA class II633037085HLA-DPA1^∗^0103PA0.800.32 (0.08)6.73 × 10^−5^memory Bhepatitis B (−)HLA-DPA1^∗^0103HLA-DPA16135424203rs6930223GT0.54−0.48 (0.12)8.39 × 10^−5^CD8^+^ GM-CSF^+^HL (+)rs7745098^∗^G*HBS1L-MYB*1094502244rs11187157CT0.430.29 (0.07)4.30 × 10^−5^mDCsIBD (+)rs11187157^∗^C*KIF11-HHEX*1094436851rs7911264TC0.530.31 (0.06)3.98 × 10^−6^mDCsIBD (+)rs7911264^∗^C*KIF11-HHEX*1226691549rs9668498AG0.250.30 (0.08)6.22 × 10^−5^TNF-αKB (+)rs10842750^∗^A*ITPR2*1578785944rs373948468ATTAT0.310.54 (0.12)2.17 × 10^−5^plasmablastCOPD (+)rs17484524^∗^G, rs7181486^∗^C*IREB2*1611223454rs11645657CG0.450.59 (0.12)4.89 × 10^−6^transitional BAD, HF, asthma (+)rs2041733^∗^T*CLEC16A*1650756881rs2076756GA0.32−0.31 (0.08)7.63 × 10^−5^CD8^+^ naiveCD (+)rs2076756^∗^G*NOD2*2062347191rs62217799TG0.69−0.29 (0.07)4.47 × 10^−5^memory BCD (+)rs4809330^∗^G*TNFRSF6B-RTEL1*[^5]

Five variants were associated with levels of cytokines or cytokine-producing T cells. A well-established rheumatoid arthritis susceptibility variant near *CTLA4* ([@bib20]) decreases CTLA4 levels in T cells ([@bib34]); here, we identify how this reduced immune checkpoint function is associated with increased levels of IL-2-producing CD8^+^ T cells. Three variants increasing TNF-α correspond to risk variants for a range of autoimmune or putative autoimmune diseases ([@bib3], [@bib12], [@bib17], [@bib77], [@bib81]). For SNP rs6930223, located in the *HBS1L-MYB* region and a known eQTL for *HBS1L*, the allele increasing GM-CSF-producing CD8^+^ cells is protective against Hodgkin's lymphoma ([@bib15]).

The cluster of inflammatory bowel disease (IBD) risk genes that gave suggestive associations in our dataset appear to create a complex immune phenotype, with increased numbers of dendritic cells and a skewing away from the naive and memory subsets in CD8^+^ T cells and B cells, respectively ([@bib16], [@bib32], [@bib45]). Moreover, the IBD risk locus *RTEL1-TNFRSF6B* has recently been fine-mapped to a variant disrupting the transcription factor binding site for EBF1 ([@bib26]), involved in B cell differentiation ([@bib22]), and we subsequently demonstrated the effect on B cell immune phenotype.

A cluster of B cell phenotype associations were shared with immune disorders of the barrier surfaces. A *CLEC16A* variant associated with increased levels of transitional B cells elevates the risk for atopic dermatitis, asthma, and hay fever ([@bib57]), and a chromosome 15 locus leading to higher plasmablast levels is associated with airway obstruction in smokers ([@bib39], [@bib47]).

Suggestive associations in the human leukocyte antigen (HLA) region overlapping with disease loci ([Tables 3](#tbl3){ref-type="table"} and [S6](#mmc7){ref-type="supplementary-material"}) included the above-described variant for TNF-α levels and a risk variant for systemic sclerosis near HLA-DRB5 and HLA-DRB6 ([@bib19]) associated with a higher percentage of lymphocytes. Finally, the HLA-DPA1^∗^0103 allele associated with protection against hepatitis B ([@bib33]) was correlated with higher levels of memory B cells, a cell type involved in vaccine response to hepatitis B in the mouse model ([@bib37]). In contrast to the predominant role of HLA in immune disease associations, however, there was a relative absence of classical HLA alleles among the eight genome-wide signals and the 13 suggestive signals for known autoimmune disease associations identified in this study.

Discussion {#sec3}
==========

In our GWAS of 54 immune traits in 489 healthy individuals, we identified eight genome-wide significant genotype-cellular immune phenotype associations that had not previously been reported. These associations were particularly enriched for functionally relevant adaptive immune phenotypes such as maturation and differentiation stages of B and T cells and Th2, Th17, and Treg cell subsets highly relevant in health and disease. For all eight associations, it was possible to identify the biologically most likely candidate gene through a combination of bioinformatics and functional analyses. The basis for understanding human immunology was until recently largely founded upon animal models. Intrinsic limitations in the fidelity of models to disease processes (i.e., interspecies barriers) have hampered translational potential, thereby spurring the call for characterization of the human immune system ([@bib64]). Our study addresses this call, and two of our genome-wide significant associations provided the crucial first evidence translating key adaptive immune pathways with clinical implications from animal models to humans. Moreover, our associations identified recently described but still poorly characterized protein families as key immune regulators in humans. Signaling cascades implicated by these associations as critical in control of the adaptive immune system are the mTOR signaling complex 1 in B cells and the mTOR signaling complex 2 and nuclear factor κB (NF-κB) pathway in T cells.

We found a coding variant in *COMMD10* associated with CD8^+^ T cell differentiation into memory cells. Members of the *COMMD* family interact with NF-κB ([@bib7]), a pathway recently shown to be essential for T cell memory ([@bib35]). CD4^+^ T helper cells differentiate into functionally distinct subsets characterized by a unique cytokine expression pattern and a lineage-associated transcription factor network. We identified genetic variants underlying baseline variation between healthy individuals in Th2, Th17, and proliferating Treg cell subsets, subsets with crucial roles in the defense against infection and susceptibility to allergy and autoimmunity. We demonstrated association of an intergenic chromosome 14 variant with Th17 and implicated *STON2*, for which we showed significant upregulation in Th17 versus Th1 cells, in controlling this interindividual variation in baseline Th17 frequency. *In vitro*, *STON2*, a component of the endocytic machinery ([@bib51]), is positively regulated by IRF4 and co-targeted by IRF4 and basic leucine zipper transcription factor ATF-like (BATF) when promoting Th17 differentiation through cooperation ([@bib18]). Our data hence extend the signaling cascade involving known Th17 controllers IRF4 and BATF in humans with *STON2* and demonstrate that this pathway is variant *in vivo* in humans. Deleting T cell mTORC2 signaling in T-*Rictor*^−/−^ mice maintains their ability to differentiate into Th1 and Th17 cells but renders T cells unable to become Th2 cells ([@bib10]). This previous observation in mice is translated into humans in our study and provides a mechanistic explanation for the association observed here for a variant disrupting a MEF2 transcription binding site in the *RICTOR* gene with baseline Th2 frequency. Treatment of mouse immature dendritic cells with interferon-lambda *in vitro* instructs these cells toward a developmental program with the capacity to trigger the proliferation of Treg cells ([@bib52]). The genotype association between the interferon-lambda locus and the proliferation of Treg cells in healthy individuals described here indicates that in humans expression of lambda interferons is variant *in vivo* in a biologically relevant range capable of influencing immune suppression. Of note, interferon-lambda stimulates the proliferation of preexisting CD25^+^Foxp3^+^ T cells rather than driving their generation *de novo* ([@bib52]), as also reflected in our data, providing an attractive therapeutic intervention point.

On the basis of our genome-wide significant associations, still poorly characterized protein families emerge for their role in the control of B cell differentiation. First, we observed association of variants throughout *LARP1B* with newly formed B cells as measured by sjKREC excision circles. LARP1B is still poorly characterized but highly resembles LARP1 ([@bib70]). LARP1 acts downstream of mTORC1 ([@bib14], [@bib24]), which, in addition to its well-known role in T cell metabolism and differentiation, controls early B cell development, survival, and metabolism in mice ([@bib29]). Our data now suggest an analogous function for the homolog LARP1B in early B cell development in humans. Our data on the effect of treatments known to induce early B cell development indicated an inverse correlation, with increased levels of LARP1B blocking early B cell differentiation. An intergenic variant on chromosome 7 was associated with memory B cell differentiation, and expression levels in B cells implicated the adjacent *SP4* gene, which is known to downregulate expression of the B cell differentiation factor *BCL2* ([@bib23], [@bib53]).

Our study identified a genetic variant regulating baseline *ex vivo* IL-6 levels. Our observations are in line with a previous study on *in vitro* cytokine levels after stimulation, where IL-6 similarly showed the strongest interindividual variation and genetic influence, and nearly all cytokine QTLs were trans-QTLs altering cytokine production indirectly rather than *cis*-QTLs altering expression of the cytokine gene itself ([@bib41]). However, genetic determinants in stimulated conditions appear distinct to those in baseline conditions and involve pattern recognition and antigen processing pathways. *ADGRL2*, which is associated with baseline IL-6 protein levels, is also known as latrophilin-2 and belongs to a branch of adhesion G-protein-coupled receptors whose precise functions remain poorly characterized. Latrophilin-1 enhances IL-6 release through exocytosis in acute myeloid leukemia, but (importantly) not in healthy human leukocytes ([@bib72]). Our data now imply the homolog latrophilin-2 in regulating IL-6 secretion in baseline conditions in healthy human individuals. The absence of any association or trend for IL-6 PBMC gene expression levels suggests a post-transcriptional mechanism or a non-hematopoietic source.

Twin and family-based studies provide evidence for both genetic and environmental factors contributing to the human immune system ([@bib6], [@bib49], [@bib55], [@bib63]). Four GWASs, with different ethnic composition, independent generation of immune phenotyping platforms, different definitions for immunological variables, and different inclusion of protein and cellular variables from the innate and/or adaptive immune system, have identified a total of 38 distinct loci associated with at least one immune trait ([@bib2], [@bib55], [@bib58], [@bib63]), and our study adds eight additional loci with a particular focus on cell subsets relevant to immune disease. Studies observed associations with mainly protein QTLs ([@bib58]), mainly cellular immune variables ([@bib2], [@bib55]) (our study) or both ([@bib63]), for predominantly the innate ([@bib58]), adaptive ([@bib2], [@bib55]) (our study), or both immune systems ([@bib63]) and for common variants ([@bib2], [@bib55], [@bib58], [@bib63]) or common and less common variants (our study).

GWASs have enabled extensive progress in the identification of risk variants for immune disorders, yet understanding the mechanism of action of these variants is a current key challenge, with indications on the putative disease mechanism known for only a small subset of established disease variants. Our results provide potential proximal inflammatory mediators between the *cis*-acting impact of a polymorphism and its established effect on immune disease susceptibility. These mechanisms implicate in particular checkpoints that are genetically variable in the physiologically relevant range and control cytokine levels and frequencies of cytokine-producing T cells. Variants controlling TNF-α levels are associated with a range of autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn disease in which the role of TNF-α is known ([@bib3], [@bib12], [@bib17], [@bib77]), and also with Kashin-Beck disease, corroborating its suspected inflammatory nature ([@bib81]). Of note, we previously demonstrated that *ITPR2*, here associated with TNF-α, controls pro-inflammatory cytokine production in mice ([@bib69]). The function of CTLA4 in suppressing IL-2 production has been long established ([@bib36]), but our results demonstrate that this checkpoint is genetically variable in the physiologically relevant range of IL-2 suppression in humans, suggesting a mechanistic explanation for association of the *CTLA4* variant with rheumatoid arthritis. Natural genetic variation in GM-CSF-producing CD8^+^ levels confers protection against Hodgkin lymphoma.

The relative absence of distinct HLA signals in our data despite known disease associations may be explained by the population, rather than clonal, level of immunophenotyping in our study. Our data suggest that overall, HLA variation does not change the global composition of the immune system. This is in line with other studies demonstrating an effect of HLA variation on the surface expression of HLA molecules in innate immune cells rather than on the frequencies of circulating immune cells ([@bib58]). For exceptions such as an HLA SNP associated with rheumatoid arthritis, Crohn disease, and enteric fever ([@bib12], [@bib17], [@bib77]), our observation of association with systemic TNF-α levels suggests a different mechanistic association instead of the classical hypothesis of modifying disease risk via antigen-specific effects.

The genotype-immune phenotype correlations in our study have important clinical implications. Genome-wide significant findings provide leads for therapeutic strategies and their translation to humans. The identification of phenotypic effects of these variants on key traits demonstrates that these genes are immunological fulcrum, where partial alterations drive physiological outcomes, an attractive property when assessing druggability. Examples are STON2 inhibition to lower Th17 levels critical in several autoimmune diseases, RICTOR stimulation to induce an anti-inflammatory and pro-regenerative context, or RICTOR inhibition in the case of Th2-mediated allergy or asthma, interferon-lambda provision to stimulate the proliferation of existing Treg cells (an attractive therapeutic intervention point for autoimmune disorders), blockade of early B cell differentiation by the La-related family homolog LARP1B, and blockade of exocytosis and release of pro-inflammatory cytokines by interfering with the latrophilin ADGRL2. Increased TNF-α production as the putative mechanism of action of rheumatoid arthritis and Crohn disease risk variants mirrors the success of anti-TNF therapies, whereas the higher levels of GM-CSF-producing CD8^+^ T cells associated with Hodgkin lymphoma protection support recent GM-CSF treatment strategies ([@bib65]).

Whereas a dataset of 489 individuals with extensive immune characterization is considered exceptionally large from an immunological point of view, it is smaller compared to current-day disease GWASs. However, this is compensated by the effects of genetic variation on quantitative traits in the human immune system (median 10% of variance) being substantially larger than on disease susceptibility, in line with a previous study ([@bib55]). This has indeed enabled us to identify eight genome-wide significant genotype-immune phenotype associations. Mapping of genetic factors controlling variation in the immune system is still in the initial discovery phase, with replication across studies yet novel and strong associations emerging from each study ([@bib43]). Our GWAS used a latest-generation imputation-based array designed to impute both common (\>5%) and less common (1%--5%) variants. Our most significant association was indeed a splicing variant with MAFs of 2%, and 39% of suggestive lead variants were less common. As most previous GWASs have captured mainly common variants, it remains to be seen whether application of the same type of array and/or whole-genome sequencing to the study of disease susceptibility will implicate more of these less common variants affecting immune phenotype in the susceptibility to disease.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CCR7 G043H7BiolegendCat\# 353205; RRID: [AB_10918624](nif-antibody:AB_10918624){#interref165}CD11c 3.9eBioscienceCat\# 46-0116-41; RRID: [AB_10598361](nif-antibody:AB_10598361){#interref0170}CD123 6H6eBioscienceCat\# 25-1239-41; RRID: [AB_1257137](nif-antibody:AB_1257137){#interref175}CD14 61D3eBioscienceCat\# 48-0149-41; RRID: [AB_1272120](nif-antibody:AB_1272120){#interref180}CD24 ML5BiolegendCat\# 311121; RRID: [AB_10915556](nif-antibody:AB_10915556){#interref185}CD27 O323eBioscienceCat\# 56-0279-41; RRID: [AB_11149315](nif-antibody:AB_11149315){#interref190}CD3 SK7eBioscienceCat\# 56-0037-42; RRID: [AB_10714978](nif-antibody:AB_10714978){#interref195}CD31 WM-59eBioscienceCat\# 12-0319-41; RRID: [AB_10670623](nif-antibody:AB_10670623){#interref200}CD38 HIT2eBioscienceCat\# 17-0389-41; RRID: [AB_1834354](nif-antibody:AB_1834354){#interref205}CD4 RPA-T4eBioscienceCat\# 61-0049-41; RRID: [AB_2574521](nif-antibody:AB_2574521){#interref210}CD8α RPA-T8eBioscienceCat\# 56-0088-41; RRID: [AB_11218867](nif-antibody:AB_11218867){#interref215}CD19 HIB19BiolegendCat\# 302241; RRID: [AB_2561381](nif-antibody:AB_2561381){#interref220}CD45Ra HI100eBioscienceCat\# 47-0458-41; RRID: [AB_10853513](nif-antibody:AB_10853513){#interref225}CD56 5.1H11BiolegendCat\# 362503; RRID: [AB_2563912](nif-antibody:AB_2563912){#interref230}CXCR5 J252DBiolegendCat\# 356903; RRID: [AB_2561812](nif-antibody:AB_2561812){#interref235}FOXP3 206DBiolegendCat\# 320113: RRID: [AB_439753](nif-antibody:AB_439753){#interref240}γδTCR B1.1eBioscienceCat\# 11-9959-41; RRID: [AB_10669048](nif-antibody:AB_10669048){#interref245}HLA-DR LN3eBioscienceCat\# 47-9956-41; RRID: [AB_1963604](nif-antibody:AB_1963604){#interref250}IFNγ 4S.B3eBioscienceCat\# 47-7319-41; RRID: [AB_10853010](nif-antibody:AB_10853010){#interref255}IgE IgE21eBioscienceCat\# 11-6986-41; RRID: [AB_10717661](nif-antibody:AB_10717661){#interref260}IgM MHM-88BiolegendCat\# 314511; RRID: [AB_961367](nif-antibody:AB_961367){#interref265}IL-17 eBio64DEC17eBioscienceCat\# 11-7179-41; RRID: [AB_10854885](nif-antibody:AB_10854885){#interref270}IL-2 MQ1-17H12eBioscienceCat\# 46-7029-41; RRID: [AB_1834420](nif-antibody:AB_1834420){#interref275}IL-4 8D4-8eBioscienceCat\# 12-7049-41; RRID: [AB_1548823](nif-antibody:AB_1548823){#interref280}Ki67 B56BDCat\# 556027; RRID: [AB_2266296](nif-antibody:AB_2266296){#interref285}CD127 eBioRDR5eBioscienceCat\# 13-1278-82; RRID: [AB_657595](nif-antibody:AB_657595){#interref290}GM-CSF BVD-21C11eBioscienceCat\# 502309; RRID: [AB_11148950](nif-antibody:AB_11148950){#interref295}IL-21 eBio3A3-N2BiolegendCat\# 12-7219-41; RRID: [AB_1582261](nif-antibody:AB_1582261){#interref300}Vα24Jα18 6B11eBioscienceCat\# 12-5806-41; RRID: [AB_1724174](nif-antibody:AB_1724174){#interref305}Naive CD4+ T Cell Isolation Kit II, humanMiltenyi Biotec130-094-131T Cell Activation/Expansion Kit, humanMiltenyi Biotec130-091-441CD24 ML5BioLegendCat\# 311103; RRID: [AB_314852](nif-antibody:AB_314852){#interref310}IgM SA-DA4eBioscienceCat\# 12-9998-42; RRID: [AB_11150964](nif-antibody:AB_11150964){#interref315}CD14 TuK4eBioscienceCat\# MHCD1418; RRID: [AB_10371748](nif-antibody:AB_10371748){#interref320}IgD IA6-2BioLegendCat\# 348209; RRID: [AB_10683460](nif-antibody:AB_10683460){#interref325}CD38 HIT2eBioscienceCat\# 17-0389-42; RRID: [AB_1834353](nif-antibody:AB_1834353){#interref330}CD27 O323eBioscienceCat\# 56-0279-42: RRID: [AB_11044789](nif-antibody:AB_11044789){#interref335}CD19 HIB19BioLegendCat\# 302209; RRID: [AB_314239](nif-antibody:AB_314239){#interref340}**Biological Samples**Serum and PBMCs of healthy volunteers[@bib8]N/ADNA samples of healthy volunteersThis paperN/APBMCs, DNA and RNA samples of healthy volunteersThis paperN/ADNA and RNA samples of multiple sclerosis patientsThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**Lymphocyte separation mediumLSM, MP Biomedicals0850494LymphoprepStemCell Technologies0786110% DMSOSigmaD2650-100MLHistopaque-1077Sigma10771Fixation-permeabilization buffereBioscience00-5523-00PMASigmaP8139IonomycinSigmaI3909-1MLGolgiStopBD Biosciences554724Cytofix/CytopermBD Biosciences55471IL-2Peprotech200-02IL-12R&D Systems219-IL-005IL-1βPeprotech200-01BIL-6Peprotech200-06IL-23Peprotech200-23EcoRINew England BiolabsR0101STrizolThermo Fisher15596026High-Capacity cDNA Reverse Transcription KitThermo Fisher4374967**Critical Commercial Assays**BAFF Quantikine ELISA kitR&D SystemsDBLYS0BV-Plex human Proinflammatory panel MSDMeso Scale DiscoveryK15049D-2Infinium HTS assay on Global Screening Array bead-chipsIllumina<https://www.illumina.com>**Deposited Data**Immune phenotypes of healthy volunteers[@bib8]Raw Data ResourceStrand file for Illumina GSA array ("GSAMD-24v1-0_20011747_A1" file)Developer: Will Rayner[http://www.well.ox.ac.uk/∼wrayner/strand/](http://www.well.ox.ac.uk/%7Ewrayner/strand/){#intref0015}1000 Genomes reference datasets \[Phase1 (2012); Phase 3 (2014)\][@bib1], [@bib71]<http://www.internationalgenome.org/>T1DGC reference panel for the HLA region, build 37[@bib31]<https://repository.niddk.nih.gov/studies/t1dgc-special/>ExSNP integrated eQTL database ("All processed eQTL data for each study" file)[@bib79]<http://www.exsnp.org/>Published dataset for splicing QTLs in whole blood ("ng.3220-S2.xlsx" file)[@bib82]N/A**Oligonucleotides**DNA detection assays for sjKRECThermo FisherCustom madeDNA detection assays for sjKRECThermo FisherCustom madeTaqMan Copy Number Reference Assay for human RNase PThermo Fisher4403326*STON2* Gene Expression AssayThermo FisherHs00263833_m1*SEL1L* Gene Expression AssayThermo FisherHs01071406_m1*LINC01467* Gene Expression AssayThermo FisherHs04403614_m1*RPL13A* Gene Expression AssayThermo FisherHs04194366_g1*SP4* Gene Expression AssayThermo FisherHs00162095_m1*SP8* Gene Expression AssayThermo FisherHs01941366_s1*LINC01162* Gene Expression AssayThermo FisherCustom made*LARP1B* Gene Expression AssayThermo FisherHs00292731_m1*IL6* Gene Expression AssayThermo FisherHs00174131_m1*MRPL19* Reference Gene Expression AssayThermo FisherHs00608519_m1*POLR2A* Reference Gene Expression AssayThermo FisherHs00172187_m1**Recombinant DNASoftware and Algorithms**FlowJo v9Tree Star<https://www.flowjo.com/>QuantaSoft v1.4Bio-Rad<http://www.bio-rad.com/>R programming language[@bib62]<https://www.R-project.org/>GenomeStudio V2011.1Illumina team<https://www.illumina.com>PLINK v1.07;v1.9[@bib61]<https://www.cog-genomics.org/plink2>SHAPEIT2[@bib9]<http://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html>IMPUTE v2.0[@bib25]<http://mathgen.stats.ox.ac.uk/impute/impute_v2.html>SNPTEST v2[@bib50]<https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html>SNP2HLA v1.0.3[@bib31]<http://software.broadinstitute.org/mpg/snp2hla/>PRSice v1.25[@bib13]<http://prsice.info/>Locuszoom standalone v1.4[@bib60]<https://genome.sph.umich.edu/wiki/LocusZoom_Standalone>SWISS v1.0.05bDeveloper: Ryan Welch<https://github.com/statgen/swiss>GEMINI v0.20.1[@bib56]<https://gemini.readthedocs.io/en/latest/>HaploReg v4 tool[@bib75]<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>RegulomeDB v1.1[@bib5]<http://www.regulomedb.org/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof. An Goris (<an.goris@kuleuven.be>). Summary results for suggestive associations are listed in [Tables S4](#mmc5){ref-type="supplementary-material"} and [S6](#mmc7){ref-type="supplementary-material"}. Summary statistics for all variants are available through the Lead Contact, Prof. An Goris (<an.goris@kuleuven.be>). Immunological data have been made available previously ([@bib8]). Requests for individual-level genotype data should be directed to and will be fulfilled pending Institutional Review Board approval and accordance with EU General Data Protection Regulation by the Lead Contact, Prof. An Goris (<an.goris@kuleuven.be>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human subjects {#sec4.3.1}

For the GWAS with immune phenotypes, we included n = 502 healthy individuals above 18 years of age, self-reported as healthy and of Caucasian origin from the same cohort in which we previously demonstrated environmental effects on the immune phenotype ([@bib8]). Exclusion criteria were cancer, autoimmunity and gastrointestinal complaints. All individuals gave written informed consent and the study was approved by the Ethics Committee of the University Hospitals Leuven. Blood samples were collected in heparin tubes and rested at 22°C for 4 h before separation of plasma and PBMCs using lymphocyte separation medium (LSM, MP Biomedicals). PBMCs were frozen in 10% DMSO (Sigma) and stored at −80°C for a maximum of 10 weeks. For B cell related expression experiments, we included four healthy donors (2 female, 2 male) for B cell subset RNA expression and 82 multiple sclerosis patients (54 female, 28 male), of which 41 were untreated and 41 were treated with interferon-beta, for total PBMC RNA expression. All individuals gave written informed consent and the study was approved by the Ethics Committee of the University Hospitals Leuven. Blood samples were collected in EDTA tubes and rested at 4°C for a maximum of 2 h before separation of plasma and PBMCs using Lymphoprep (StemCell Technologies, Inc.). PBMCs were frozen in 10% DMSO (Sigma) and stored in liquid nitrogen. For the T helper differentiation experiment, PBMCs from three anonymous blood bank donors were isolated from leukocyte cones using Histopaque-1077 (Sigma).

Method Details {#sec4.4}
--------------

### Flow cytometry phenotyping {#sec4.4.1}

Thawed cells were stained with antibodies as listed in the Key Resource Table. Ki67 and Foxp3 staining was performed after treatment with fixation-permeabilization buffer (eBioscience). Cytokine staining was performed after *ex vivo* stimulation for 5 h in 50 ng/ml PMA (Sigma) and 500 ng/ml ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences). Stimulated cells were surface stained, fixed and permeabilized with Cytofix/Cytoperm (BD), before staining for cytokines. Additional cells were stimulated for 72 h for supernatant assessment by MSD (see below). Data were acquired on a BD FACSCantoII and analyzed with FlowJo (Tree Star).

### Serological assessment {#sec4.4.2}

Plasma samples collected were stored at −80°C. Circulating levels of B cell activation factor (BAFF) were measured using a human BAFF Quantikine ELISA (R&D Systems). Cytokine plasma concentrations were quantified by electrochemiluminescence immunoassay using the V-Plex human Proinflammatory panel (Meso Scale Discovery). All reagents and standards were provided by each manufacturer. Samples and standards were prepared according to each manufacturer's instructions.

### sjKREC and sjTREC levels {#sec4.4.3}

Droplet digital PCR (Bio-Rad, Hercules, CA) with DNA detection assays (Thermo Fisher) for sjKREC, sjTREC (both custom made, sequences available on request) and TaqMan Copy Number Reference Assay for human RNase P was performed using 250 ng of restriction digested (EcoRI, New England Biolabs) genomic DNA according to the manufacturer's instructions. Relative quantity of sjKREC and sjTREC per (RNaseP / 2) ^∗^ 100,000 cells was measured with QuantaSoft v1.4 (Bio-Rad). Correlation among n = 12 duplicate measurements was 0.81 for sjKREC and 0.92 for sjTREC. sjKREC is correlated with B cells (r^2^ = 0.33), in particular transitional (r^2^ = 0.14) and naive (r^2^ = 0.22) B cells, whereas sjTREC is correlated with RTE CD4^+^ (r^2^ = 0.15) and CD8^+^ (r^2^ = 0.13) T cells.

### Immune phenotype data processing {#sec4.4.4}

In order to obtain normally distributed data for all traits, a rank-based inverse normal transformation was applied to n = 51 parameters using the rank and qnorm functions in the R statistical software package. For cytokines, levels below the detection threshold were set as equal to the detection threshold. Three cytokines with levels below or equal to the detection threshold in a large subset of individuals (IL-2, IL-4 and IL-12) deviated from a normal distribution even after rank-based inverse normal transformation and were hence transformed into a binary variable representing positive (above detection threshold) or negative (below or equal to detection threshold) measurements. An overview of the 54 immunological parameters is given in [Table S1](#mmc2){ref-type="supplementary-material"}. Sex was taken into account as a covariate in the analyses.

### Genotyping {#sec4.4.5}

DNA was extracted from total blood using standard methods with an in-house protocol. Concentration was measured with Nanodrop 2000 (Thermo Scientific) and samples were diluted at 100 ng/μl in TE 10/1. All participants were genotyped for 700,078 variants using the Infinium© HTS assay on Global Screening Array bead-chips (Illumina). Genotype calling was done using GenomeStudio V2011.1 software. Genotyping, genotype calling, quality control and imputation were performed together with 217 individuals from the same population included in a separate GWAS for imaging traits (Smets I. et al., manuscript in preparation) to improve imputation accuracy especially for lower allele frequency spectra. Cluster plots were inspected for genome-wide significant directly genotyped lead SNPs or SNPs in LD (r^2^ \> 0.3 and p \< 10^−4^) with imputed lead SNPs. "Singleton" imputed lead SNPs (no r^2^ \> 0.6 with other directly genotyped or imputed SNPs) were genotyped using a Taqman assay.

### Expression experiments {#sec4.4.6}

Naive CD4^+^ T cells were negatively isolated from PBMCs of three healthy donors using the human Naive CD4^+^ T Cell Isolation Kit II (Miltenyi Biotec). The purity was measured using flow cytometry (95%--98%). Differentiation of T helper cells into either Th1 or Th17 was carried out using 50 IU/ml IL-2, 1:5 anti-CD2/CD3/CD28 beads (T cell activation/expansion kit, Miltenyi Biotec) and lineage-skewing cytokines: 20 ng/ml IL-12 for Th1 and 80ng/ml IL-1β/IL-6/IL-23 for Th17 cells. IL-12 was purchased from R&D Systems, all other cytokines were purchased from PeproTech. Cells were harvested after 6 days for mRNA. Taqman gene expression assays (Thermo Fisher) were used to measure the mRNA levels of *STON2* (Hs00263833_m1), *SEL1L* (Hs01071406_m1) and *LINC01467* (Hs04403614_m1), with *RPL13A* (Hs04194366_g1) as the reference gene.

PBMCs from four healthy donors were sorted using a B cell panel using the following antibodies: CD24-FITC (BioLegend), IgM-PE (EBioscience), CD14-PE-Cy5.5 (EBioscience), IgD-PE-Cy7 (BioLegend), CD38-APC (EBioscience), CD27-AF-700 (EBioscience), CD19-PE-Cy5 (BioLegend). Cells were sorted into transitional, naive, switched memory and unswitched memory B cells. RNA was extracted from these sorted cells using TRIzol reagent (Thermo Fisher). The same extraction method was used for extracting RNA from PBMCs of 173 of the healthy individuals and 82 multiple sclerosis patients. RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). Droplet digital PCR (Bio-Rad) was performed using up to 50 ng cDNA according to the manufacturer's instructions with predesigned gene expression assays (Thermo Fisher) for *SP4* (Hs00162095_m1), *SP8* (Hs01941366_s1), *LARP1B* (Hs00292731_m1) and *IL6* (Hs00174131_m1), a custom Taqman gene expression assay for *LINC01162*, and assays for reference genes *POLR2A* (Hs00172187_m1) and *MRPL19* (Hs00608519_m1). Relative quantity of *SP4*, *SP8* and *LINC01162* versus *POLR2A* and of *LARP1B* and *IL6* versus *MRPL19* was measured with QuantaSoft v1.4 (Bio-Rad).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Sample size and power {#sec4.5.1}

The sample size of n = 502 healthy individuals provided 80% power to detect at genome-wide significance level (p \< 5 × 10^−8^) genetic variants explaining ≥ 7.8% of variance in a trait, in line with realistic effect sizes previously observed ([@bib55]).

### Genotyping quality control {#sec4.5.2}

Sample QC was performed using PLINK v1.07 (see also [Figure S1](#mmc1){ref-type="supplementary-material"}). Gender was verified using the mean homozygosity rate across X chromosome markers. Samples with genotype call rate \< 98% or excess heterozygosity (\> 5 standard deviations from the sample mean) were excluded based on the set of variants meeting minor allele frequency (MAF) ≥ 5%, genotyping success rate ≥ 98% and Hardy-Weinberg p \> 10^−6^ (n = 3, [Figure S1](#mmc1){ref-type="supplementary-material"}A). The biological relationship of all individuals was verified based on pairwise identity by descent (IBD), and identical or related individuals were removed (n = 8, [Figure S1](#mmc1){ref-type="supplementary-material"}B). For this analysis, regions of extended LD ([@bib59], [@bib76]) were removed, and the dataset was pruned so that no pair of SNPs within a given window of 50kb is correlated (r^2^ \> 0.2). For each pair showing cryptic relatedness (defined as IBD \> 0.1875), the individual with the lower genotyping call rate was removed from further analysis. In addition, ethnic outliers from the European cluster as assessed by principle component analysis (PCA) combined with 1000 Genomes populations Phase 1 ([@bib1]) were removed (n = 2, [Figure S1](#mmc1){ref-type="supplementary-material"}C). Both IBD estimation and clustering for population stratification were based on a pruned set of independent markers (defined by pairwise r^2^ \< 0.2). A total of n = 489 healthy controls remained in the analysis.

Variant QC was performed in the cleaned sample set. Variants with minor allele frequency (MAF) \< 1%, call rate \< 98% for common variants (MAF \> 5%) or \< 99% for low frequency variants (1% ≤ MAF ≤ 5%) or significant deviation from Hardy-Weinberg equilibrium (HWE) (p \< 10^−6^) were excluded. A total of 500,542 SNPs remained in the analysis. Alleles were aligned to b37 forward strand alleles to be in accordance with the imputation reference panel of haplotypes (strand file used: [http://www.well.ox.ac.uk/∼wrayner/strand/](http://www.well.ox.ac.uk/%7Ewrayner/strand/){#intref0125}).

### Genotype imputation {#sec4.5.3}

Before imputation genotypes were pre-phased using SHAPEIT2 ([@bib54]) with the European 1000 Genomes October 2014 haplotypes \[Phase 3 integrated variant set release in NCBI build 37 (hg19) coordinates\] as a reference panel (<http://www.internationalgenome.org/>). For pre-phasing, default parameters were used for the autosomes and pseudoautosomal regions of the X chromosome, whereas the '--chrX' flag was used for the non-pseudoautosomal region of the X chromosome.

The imputation into the estimated haplotypes was performed using the IMPUTE v2.0 software package ([@bib25]) and all 1000 Genomes October 2014 haplotypes \[Phase 3 integrated variant set release in NCBI build 37 (hg19) coordinates\] (<http://www.internationalgenome.org/>). All samples were pre-phased and imputed in a single batch, to avoid batch effects attributable to the imputation process. To make computation feasible during imputation, each chromosome was split into 5-Mb chunks with default parameters for the autosomal and pseudoautosomal regions and the '-chrX' flag for the non-pseudoautosomal regions of the X chromosome.

The MHC region on chromosome 6 (chr 6:29494896-33160424) was extracted from the post-QC directly genotyped dataset. Classical Human Leukocyte Antigen (HLA) alleles, amino acid polymorphisms and SNPs in the MHC region were imputed with SNP2HLA v1.0.3 and the T1DGC reference panel (build 37) ([@bib31]). Imputed HLA variants were merged with directly genotyped variants and IMPUTE v2.0 imputed variants in the region leading to 132,064 unique variants, including 424 classical HLA alleles and 1,276 HLA amino acid changes.

### GWAS analysis {#sec4.5.4}

A genome-wide association analysis of directly genotyped and imputed variants was performed for each trait. An additive genetic model was fitted at each variant with gender as covariate using SNPTESTv2 software with the frequentist test and the expectation-maximization method (as implemented in SNPTEST) to account for genotype uncertainty in the regression analyses of the imputed SNPs and especially low frequency ones ([@bib50]). The Phase 3 haplotypes in SNPTESTv2 contain multi-allelic variants, and SNPTEST processes these variants to create multiple bi-allelic variants. For example, a tri-allelic SNP with 3 alleles (REF, ALT1, ALT2) will have been recoded as two bi-allelic SNPs, the first one with alleles REF and ALT1, and the second SNP with alleles REF and ALT2. For markers on the X chromosome, the association test was performed assuming a standard model of complete X inactivation and an equal effect size in men and women. In this model, male genotypes are coded as 0/1 and female genotypes as 0/0.5/1.

The association results were quality controlled by removing the following variants: MAF \< 1%, minor allele count ≤ 6 and imputation quality score (SNPTEST Proper_INFO) \< 0.4. Results were obtained for a maximum of 10,246,977 autosomal variants, including n = 6,994,434 common variants (n = 6,086,969 SNPs and n = 907,465 indels) and n = 3,252,543 less common variants (n = 2,962,706 SNPs and n = 289,837 indels) (see also [Figure S2](#mmc1){ref-type="supplementary-material"}). The genomic control inflation factor (λ~GC~) had a median of 1.012 (range 0.995 - 1.033) suggesting population stratification had limited influence on the test statistical distribution. Associations were considered genome-wide significant for p \< 5 × 10^−8^ and suggestive for p \< 10^−4^. The lead SNP was identified as the SNP with smallest P value in a 1-Mb region.

Chromosome X results with MAF ≥ 0.01, MAC \> 6 and INFO ≥ 0.4 were obtained for up to 353,613 variants including n = 224,865 common variants (n = 190,475 SNPs and n = 34,390 indels) and n = 128,748 less common variants (n = 113,977 SNPs and n = 14,771 indels).

Percentage of the variance explained for each genome-wide significant variant was calculated on the basis of a generalized linear model in PRSice v1.25 as the r^2^ of the full model (genetic variant and gender) minus r^2^ of the baseline model (only including gender).

### Conditional analysis and LD pruning {#sec4.5.5}

Conditional analyses were performed using SNPTESTv2 for SNPs in a 2-Mb region around each genome-wide significant lead SNP in a linear regression additive model conditioning on the lead SNP. Quality control was applied as above.

Regional association plots were generated using the stand-alone LocusZoom version 1.4 with 1000 Genomes genotypes (1000G_Nov2014, EUR) build hg19 as LD resource and refflat for gene annotation.

LD-based clumping was performed for all autosomal variants reaching suggestive association (p \< 10^−4^) per trait and across traits using SWISS version 1.0.05b. Variants in LD (r^2^ \> 0.1 based on the build-in 1000G_2014-11_EUR) within 1-Mb from the most significantly associated variant were removed so that independent variants remain. For N = 49 variants for which no LD information was available in the 1000G EUR dataset, the 1000G ALL dataset was used instead.

### Variant annotation {#sec4.5.6}

Variants were annotated for location, functional consequences, and predicted characteristics with GEMINI ([@bib56]) version 0.20.1 with assembly GRCh37.p13, RefSeq 87_GRCh37, dbSNP 137, and VEP v.87. HaploReg v4 tool was used to examine whether variants or variants in LD (r^2^ \> 0.8) are coding, conserved (as predicted as such by both GERP and SiPhy scores), or overlapping with quantitative trait loci. Additionally, ExSNP integrated eQTL database of 16 publicly available human QTL sources ([@bib79]) and QTL studies on relevant immunological cell subsets (listed in Lotta et al. ([@bib46])) were queried. For variants listed in the main tables, the LD-based query (variant or variant with r^2^ \> 0.8) in ExSNP was used; for the full list of suggestive variants the full ExSNP dataset was downloaded and cross-linked for overlap. For splicing QTLs in whole blood, a published dataset was used ([@bib82]). Disruption of a regulatory motif was evaluated using RegulomeDB v1.1.

The SWISS software version 1.0.05b was used to ascertain whether there is LD (r^2^ \> 0.8 based on the build-in 1000G_2014-11_EUR) between suggestive variants in our study and known associations reaching genome-wide significance with other traits in the build-in EBI GWAS catalog GRCh37p13.

### Expression analysis {#sec4.5.7}

For *in vitro* differentiated Th1 and Th17 cells from each of three donors, qPCR was performed in triplicate, the average of which is plotted. Two-tailed paired t test was used for comparison of the log-transformed relative quantity (RQ) in Th17 versus Th1 differentiated cells, with the average RQ in Th1 set as equal to 1. For sjKREC and log-transformed *LARP1B* relative quantity in 82 multiple sclerosis patients, linear regression with covariates age, gender and treatment was applied.

Data and Software Availability {#sec4.6}
------------------------------

Immunological data have been made available previously ([@bib8]). Summary results for suggestive associations are listed in the [Tables S4](#mmc5){ref-type="supplementary-material"} and [S6](#mmc7){ref-type="supplementary-material"}. Summary statistics for all variants are available through the Lead Contact, Prof. An Goris (<an.goris@kuleuven.be>).

The following publicly available software packages were used for the analyses: Plink v1.07 ([@bib61]), SHAPEIT ([@bib54]), IMPUTE v2.0 ([@bib25]), SNPTESTv2 ([@bib50]), SNP2HLA v1.0.3 ([@bib31]), LocusZoom standalone, SWISS version 1.0.05b, GEMINI version 0.20.1. ([@bib56]), Haploreg v4.1, and RegulomeDB v1.1. The following publicly available datasets were used for the analyses: strand file for Illumina GSA array: [http://www.well.ox.ac.uk/∼wrayner/strand/](http://www.well.ox.ac.uk/%7Ewrayner/strand/){#intref0145}; 1000 Genomes reference datasets: <http://www.internationalgenome.org/>; the T1DGC reference panel for the HLA region (build 37) ([@bib31]); the ExSNP dataset ([@bib79]); and the EBI GWAS catalog GRCh37p13.
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[^3]: We observed nominal significance for five genome-wide significant associations previously reported in the Sardinian population ([@bib55]). Trait names in Orrù et al. study: AC, absolute count; %GP, percentage of grandparental cells; NK, natural killer (cells); %P, percentage of parental cells; TD, terminally differentiated. BETA, effect; Chr, chromosome; EA, effect allele; EAF, effect allele frequency; NEA, non-effect allele; Pos, position in GRCh37; rsID, reference SNP identification; SE, standard error.

[^4]: Variants associated with p \< 5 × 10^−8^. SNPs rs17612648 and rs113116201 at the *PTPRC* locus are in LD (r^2^ = 0.62 in EURs, r^2^ = 1 in CEU) and conditional analyses were not able to distinguish between them (see also [Table S3](#mmc4){ref-type="supplementary-material"}). Annotation indicates whether the variant is or is in LD with (r^2^ \> 0.8) a coding variant (Co) or known splicing or expression quantitative trait locus (Q) or is conserved (Cs), whether the variant disrupts a regulatory motif (R), whether the variant is located in the candidate gene (G) or the candidate gene is the nearest gene to the variant (N), and whether the candidate gene is supported by biological evidence in the literature (L) or by expression data obtained in this study (E). For all three regions where both trait and variant have appropriate equivalents in previous GWASs, our findings replicated with nominal significance (p \< 0.05) or showed a trend in the same direction (see also [Table S2](#mmc3){ref-type="supplementary-material"}). BETA, effect; Chr, chromosome; EA, effect allele; EAF, effect allele frequency; INFO, imputation quality, with 1 for directly genotyped variants; n, number of individuals with genotype and immune phenotype; NEA, non-effect allele; Pos, position in GRCh37; rsID, reference SNP identification; SE, standard error; % var, percentage of variance explained.

[^5]: Suggestive (p \< 10^−4^) genotype-immune phenotype correlations in LD (r^2^ \> 0.8) with established immune disease susceptibility SNPs (+, susceptibility; −, protection). See also [Tables S4](#mmc5){ref-type="supplementary-material"} and [S6](#mmc7){ref-type="supplementary-material"} for all non-HLA and HLA suggestive associations, respectively, and [Table S5](#mmc6){ref-type="supplementary-material"} for all suggestive associations in LD with a variant for any disease in the EBI GWAS catalog. BETA, effect; EA, effect allele (P indicates present and A absent for HLA allele); EAF, effect allele frequency; NEA, non-effect allele; Pos, position in GRCh37; rsID, reference SNP identification; SE, standard error. Traits and disease associations: AD, atopic dermatitis ([@bib57]), asthma ([@bib57]); CD, Crohn disease ([@bib16], [@bib77]); COPD, chronic obstructive pulmonary disorder obstruction ([@bib39], [@bib47]); EF, enteric fever ([@bib12]), hepatitis B ([@bib33]); HF, hay fever ([@bib57]); HL, Hodgkin lymphoma ([@bib15]); IBD, inflammatory bowel disease ([@bib32], [@bib45]); KB, Kashin-Beck disease ([@bib81]); mDCs, myeloid dendritic cells; Ps, psoriasis ([@bib3]); RA, rheumatoid arthritis ([@bib17], [@bib20]); SSc, systemic sclerosis ([@bib19]).
